<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00648648</url>
  </required_header>
  <id_info>
    <org_study_id>1775-001</org_study_id>
    <secondary_id>2007_611</secondary_id>
    <nct_id>NCT00648648</nct_id>
  </id_info>
  <brief_title>A Dose Escalation Study of MK1775 in Combination With Either Gemcitabine, Cisplatin, or Carboplatin in Adults With Advanced Solid Tumors (MK-1775-001 AM7)</brief_title>
  <official_title>A Phase I Dose Escalation Study Evaluating MK1775 in Both Monotherapy and in Combination With Either Gemcitabine, Cisplatin, or Carboplatin in Adult Subjects With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will investigate MK1775 alone and in combination with one of the following three
      drugs: gemcitabine, cisplatin, and carboplatin in patients with advanced solid tumors. The
      purpose of the study is to test safety and tolerability of MK1775 alone and in combination,
      and to find the maximum tolerated dose (MTD) of MK1775 as monotherapy and in combination
      therapy.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2008</start_date>
  <completion_date type="Actual">January 2014</completion_date>
  <primary_completion_date type="Actual">January 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with dose limiting toxicities</measure>
    <time_frame>Cycle 1 (14 days for monotherapy and 21-28 days for combination therapy)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline in biomarkers PHH3, CDC2, and pCDC2</measure>
    <time_frame>At screening and Cycle 1 dependent upon tumor type</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma concentration of MK1775</measure>
    <time_frame>Day 1 pre- and post-dose, Day 2, and Day 3 of Cycle 1 monotherapy, and Day 2 and 3 of combination therapy (optional at Days 4 and 5)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Urine concentration of MK-1775</measure>
    <time_frame>Up to 24 hours post Day 1 dose of monotherapy</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with objective response</measure>
    <time_frame>Tumor will be measured on the first day of every-other treatment cycle, or as clinically indicated</time_frame>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">203</enrollment>
  <condition>Solid Tumors</condition>
  <arm_group>
    <arm_group_label>Part 1: MK1775 single dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part 1: MK1775 capsules will be given on Day 1 of a 14-day cycle: starting dose of MK1775 is 325 mg and will escalate up to 1300 mg or until MTD achieved</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 3: Confirmation and Expansion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part 3: Patients will be treated with MTD of MK1775 from Part 2-B in combination with the MTD from Part 2-B of either gemcitabine, cisplatin, or carboplatin.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2-A Gemcitabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Starting single dose of MK1775, 100 mg with gemcitabine IV infusions dosage ranging from 1000 mg/m^2 to 600 mg/m^2 in a 28-day cycle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2-A Cisplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Starting single dose of MK1775, 100 mg with cisplatin IV infusion dosage ranging from 75 mg/m^2 to 50 mg/m^2 in a 21-day cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2-A Carboplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Starting single dose of MK1775, 100 mg with carboplatin IV infusion dosage ranging from AUC/time curve of 5 mg/min/mL to AUC 3 in a 21-day cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2-B Gemcitabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Starting multiple dose of MK1775, 50 mg with gemcitabine IV infusions dosage ranging from 1000 mg/m^2 to 600 mg/m^2 in a 28-day cycle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2-B Cisplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Starting multiple dose of MK1775, 50 mg with cisplatin IV infusion dosage ranging from 75 mg/m^2 to 50 mg/m^2 in a 21-day cycle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2-B Carboplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Starting multiple dose of MK1775, 75 mg with cisplatin IV infusion dosage ranging from AUC/time curve of 5 mg/min/mL to AUC 3 in a 21-day cycle.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MK1775</intervention_name>
    <description>Dose escalation study. Part 1: MK1775 capsules will be given on Day 1 of a 14-day cycle: starting dose of MK1775 is 325 mg and will escalate up to 1300 mg or until MTD achieved. Dose Levels for MK1775: 325 mg, 650 mg, and 1300 mg.</description>
    <arm_group_label>Part 1: MK1775 single dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gemcitabine</intervention_name>
    <description>gemcitabine - IV infusions dosage ranging from 1000 mg/m^2 to 600 mg/m^2 in a 28-day cycle. Dose Levels for Gemcitabine: 1000 mg/m^2, 800 mg/m^2, 600 mg/m^2</description>
    <arm_group_label>Part 2-A Gemcitabine</arm_group_label>
    <arm_group_label>Part 2-B Gemcitabine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
    <description>cisplatin - IV infusion dosage ranging from 75 mg/m^2 to 50 mg/m^2 in a 21-day cycle. Dose Levels for cisplatin 75 mg/m^2, 60 mg/m^2, 50 mg/m^2</description>
    <arm_group_label>Part 2-A Cisplatin</arm_group_label>
    <arm_group_label>Part 2-B Cisplatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carboplatin</intervention_name>
    <description>carboplatin - IV infusion dosage ranging from AUC/time curve of 5 mg/min/mL to AUC 3 in a 21-day cycle. Dose levels for carboplatin: AUC 5, AUC 4, AUC 3</description>
    <arm_group_label>Part 2-A Carboplatin</arm_group_label>
    <arm_group_label>Part 2-B Carboplatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MK1775</intervention_name>
    <description>Part 2-A: consists of three treatment arms, each combining a single starting dose of MK1775, 100 mg in a 21-28 day cycle. Dose Levels for MK1775: 50 mg, 100 mg, 200 mg, 325 mg, 475 mg, 675 mg, 900 mg, 1200 mg, 1600 mg (undetermined interim doses are allowed)</description>
    <arm_group_label>Part 2-A Gemcitabine</arm_group_label>
    <arm_group_label>Part 2-A Cisplatin</arm_group_label>
    <arm_group_label>Part 2-A Carboplatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MK1775</intervention_name>
    <description>Part 2-B: consists of three treatment arms, each combining a starting dose of MK1775, 50 mg (for gemcitabine) in a 28 day cycle. Dose Levels for MK1775: 25 mg, 50 mg, 100 mg, 125 mg, 150 mg, 200 mg, 250 mg, 325 mg, 425 mg (undetermined interim doses are allowed)</description>
    <arm_group_label>Part 2-B Gemcitabine</arm_group_label>
    <arm_group_label>Part 2-B Cisplatin</arm_group_label>
    <arm_group_label>Part 2-B Carboplatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MK1775</intervention_name>
    <description>Part 3: consists of treatment with MTD of MK1775 from Part 2-B.</description>
    <arm_group_label>Part 3: Confirmation and Expansion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gemcitabine</intervention_name>
    <description>gemcitabine - IV infusions dosage ranging from 1000 mg/m^2 to 600 mg/m^2 in a 28-day cycle.</description>
    <arm_group_label>Part 3: Confirmation and Expansion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
    <description>cisplatin - IV infusion dosage ranging from 75 mg/m^2 to 50 mg/m^2 in a 21-day cycle.</description>
    <arm_group_label>Part 3: Confirmation and Expansion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carboplatin</intervention_name>
    <description>carboplatin - IV infusion dosage ranging from AUC/time curve of 5 mg/min/mL to AUC 3 in a 21-day cycle.</description>
    <arm_group_label>Part 3: Confirmation and Expansion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject must have a histologically confirmed metastatic or locally advanced solid
             tumor, progressed despite standard therapy, or for which standard therapy does not
             exist

          -  Subject is at least 18 years old

          -  Subject must have performance status of &lt;=1 on the ECOG Performance Scale

          -  Female subjects must not be pregnant

        Exclusion Criteria:

          -  Subject has had chemotherapy, radiotherapy, or biological therapy within 4 weeks prior
             to entering the study or who has not recovered from adverse events due to agents given
             more than 4 weeks earlier

          -  Subject is participating or has participated in a study with an investigational
             compound or device within 30 days

          -  Subjects with active CNS metastases and/or carcinomatous meningitis are excluded.
             However, subjects with CNS metastases who have completed a course of therapy would be
             eligible for the study provided they are clinically stable for 1 month prior to entry

          -  Subject with a primary central nervous system tumor

          -  Subject is allergic to any of the components of the combination study therapy or its
             analogs

          -  Participant has had prescription or non-prescription drugs or other products known to
             be metabolized by CYP3A4 that cannot be discontinued prior to Day 1 of dosing and
             withheld throughout the study until 2 weeks after the last dose of study medication.
             Medications of particular concern are inhibitors of CYP3A4 (azole antifungals
             [ketoconazole, itraconazole], macrolide antibiotics [erythromycin, clarithromycin],
             cimetidine, aprepitant, HIV protease inhibitors, nefrazodone, and the following
             inducers of CYP3A4: phenytoin, barbiturates and rifampicin, and substrates of CYP3A4
             including statins (lovastatin, simvastatin), midazolam, terfenadine, astemizole, and
             cisapride

          -  Subject is a regular user (including &quot;recreational use&quot;) of any illicit drugs or had a
             recent history (within the last year) of drug or alcohol abuse

          -  Subject is pregnant or breastfeeding, or expecting to get pregnant during the time the
             study will be ongoing

          -  Subject is (HIV)-positive

          -  Subject has a history of Hepatitis B or C

          -  Subject has symptomatic ascites or pleural effusion. A subject who is clinically
             stable following treatment for these conditions is eligible

          -  Subject must not have prior radiation therapy to more than 30% of the bone marrow and
             must have recovered for at least 3 weeks from the hematologic toxicity of prior
             radiotherapy

          -  Subject has had a prior stem cell or bone marrow transplant

          -  Subject has received more than 4 prior cytotoxic chemotherapy regimens

          -  Participant has a history suggestive of Li-Fraumeni Syndrome
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Canada</country>
    <country>Netherlands</country>
    <country>United States</country>
  </removed_countries>
  <verification_date>February 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 26, 2008</study_first_submitted>
  <study_first_submitted_qc>March 28, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 1, 2008</study_first_posted>
  <last_update_submitted>February 3, 2015</last_update_submitted>
  <last_update_submitted_qc>February 3, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 4, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>May 11, 2018</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

